.png)
.png)
A blood test, a telephone call and a series of investigations that followed within days changed the course of Ian Swift’s life. The 56-year-old retired firefighter and Royal Navy veteran was diagnosed with bowel cancer in March 2026, less than four weeks after his initial blood test. His experience stands in marked contrast to the prolonged uncertainty that has become familiar to patients navigating overstretched NHS services. At the Shrewsbury and Telford Hospital NHS Trust (SaTH), the speed of his diagnosis reflects a wider operational transformation, one that has taken the organisation from the bottom of national cancer diagnosis rankings to among the country's strongest performers.
In February 2025, SaTH ranked 119th out of 119 trusts for the proportion of patients receiving a definitive diagnosis or having cancer ruled out within 28 days of an urgent referral. By August 2026, it had reached fifth place. Its performance stood at 87.8%, comfortably above the national Faster Diagnosis Standard of 80%. The improvement in treatment times has also been substantial. Some 76.7% of patients began treatment within 62 days of referral, placing the trust 41st among 122 reporting providers, compared with 112th 18 months earlier. That represents a rise of 71 places.
The distinction between diagnosis and treatment matters. The trust has exceeded the 28-day standard, but its 62-day performance remains below the national target of 85%. Its stated ambition is to reach 80% by March 2027 before meeting the national standard in the following financial year. The figures therefore describe a significant recovery, rather than a completed one.
For Swift, the improvement was experienced through a sequence of appointments that moved quickly. Two or three days after his first blood test, he was asked to undertake a quantitative faecal immunochemical test. A telephone call from his doctor the following evening led to further investigations. He subsequently attended Princess Royal Hospital in Telford for an anoscopy and colonoscopy, with the bowel cancer diagnosis confirmed in March. He has since undergone surgery and chemotherapy and is now in remission.
His account also illustrates the importance of communication during a suspected cancer pathway. He described being kept informed about what was happening and never feeling left waiting without an explanation. Following treatment, he has attended Men Like Us, a cancer support group run by the trust, and received assistance from Lingen Davies and Macmillan Cancer Support. The clinical pathway brought him to a diagnosis quickly, while the support networks helped him manage what followed.
The institutional changes behind this progress are more instructive than the ranking itself. According to the trust's lead cancer nurse, Siwan Owen, improvements in radiology and pathology turnaround times have been central. These departments often determine how quickly a suspected cancer referral advances. A scan may be available, but its clinical value is delayed if reporting capacity is insufficient. SaTH has worked to reduce the interval between diagnostic requests, investigations and results, with many scans now completed and reported within ten days.
Community diagnostic capacity has also changed how patients enter the pathway. General practitioners can refer patients for investigations through community diagnostic services, reducing reliance on conventional hospital appointments. This matters in a system where diagnostic backlogs frequently extend the period between an initial referral and a definitive clinical decision. Moving appropriate investigations closer to patients can release pressure on acute hospitals while making access more convenient.
A further element is the TRIOMIC colorectal cancer study at the Community Diagnostic Centre in Telford. Run by SaTH in partnership with medical technology company Origin Sciences, the UK-first trial is developing a test using samples collected through the Oricol device to identify abnormal cells associated with colorectal cancer and significant polyps. Its purpose is to reduce the number of patients who need an invasive colonoscopy. The test remains under investigation and cannot independently establish a definitive cancer diagnosis. Nevertheless, the redesigned pathway surrounding the study has helped increase clinic capacity, with the first outpatient appointment for colorectal patients falling from an average of 14 days to five in early 2026.
This arrangement deserves attention from NHS commissioners and the life sciences sector. The collaboration shows how an NHS provider and a technology company can work together around a defined clinical problem. It also raises an important question about the conditions under which such partnerships can be replicated. External investment has helped fund facilities and additional staff at Telford. Other trusts facing similar pressures may not have access to the same commercial partnership or research infrastructure. Replication will require careful consideration of funding, clinical evidence, regulatory requirements and the capacity to integrate new tests into established pathways.
For NHS leaders, the wider lesson concerns the organisation of diagnostic work. Expanding scanning equipment or recruiting additional clinicians will have limited effect if the stages between referral, investigation, reporting and treatment remain disconnected. SaTH's experience suggests that pathway management, specialist nursing capacity and access to diagnostics must be considered together. Its progress also demonstrates the importance of giving clinical teams the authority and resources to identify delays and redesign services around them.
The benefits extend beyond patients who receive a positive diagnosis. A suspected cancer referral creates a period of uncertainty that can affect sleep, employment and family life. When investigations establish that cancer is absent, a faster answer can end weeks of anxiety. For those diagnosed with the disease, earlier identification can improve access to treatment when cancer remains at a more manageable stage, although survival outcomes depend on tumour biology, stage and the treatment available.
There is a wider political implication. The NHS is under pressure to demonstrate that additional investment and reform can produce measurable improvements in patient access. SaTH offers evidence that operational change can deliver results, even in a trust that began from an exceptionally weak position. Yet the remaining gap in its 62-day performance is a reminder that progress in diagnosis does not automatically resolve delays further along the pathway.
The real measure of this turnaround will be whether the trust can sustain its performance as referral volumes grow and treatment capacity comes under pressure. For the wider NHS, the challenge is to understand which parts of the model can be adopted elsewhere, and what resources they require. A fifth-place diagnosis ranking is a considerable achievement. Making timely cancer care routine across the health service would be a much larger test of institutional capacity.